120 related articles for article (PubMed ID: 11308263)
1. Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells.
Withoff S; Bijman MN; Stel AJ; Delahaye L; Calogero A; Jonge MW; Kroesen BJ; Leij L
Br J Cancer; 2001 Apr; 84(8):1115-21. PubMed ID: 11308263
[TBL] [Abstract][Full Text] [Related]
2. The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.
Stel AJ; Kroesen BJ; Jacobs S; Groen H; de Leij LF; Kluin-Nelemans HC; Withoff S
J Immunol; 2004 Nov; 173(10):6009-16. PubMed ID: 15528335
[TBL] [Abstract][Full Text] [Related]
3. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
5. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
Shan D; Gopal AK; Press OW
Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
8. The p38 mitogen-activated protein kinase is activated by ligation of the T or B lymphocyte antigen receptors, Fas or CD40, but suppression of kinase activity does not inhibit apoptosis induced by antigen receptors.
Salmon RA; Foltz IN; Young PR; Schrader JW
J Immunol; 1997 Dec; 159(11):5309-17. PubMed ID: 9548470
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
James SE; Orgun NN; Tedder TF; Shlomchik MJ; Jensen MC; Lin Y; Greenberg PD; Press OW
Blood; 2009 Dec; 114(27):5454-63. PubMed ID: 19880489
[TBL] [Abstract][Full Text] [Related]
11. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
12. CD20-targeted therapy: the next generation of antibodies.
van Meerten T; Hagenbeek A
Semin Hematol; 2010 Apr; 47(2):199-210. PubMed ID: 20350667
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of monoclonal antibodies against human CD20 in Balb/c mice.
Sepehr KS; Baradaran B; Majidi J; Abdolalizadeh J; Aghebati L; Shahneh FZ
Hum Antibodies; 2012; 21(3-4):57-64. PubMed ID: 23549022
[TBL] [Abstract][Full Text] [Related]
14. CD20-induced B cell death can bypass mitochondria and caspase activation.
van der Kolk LE; Evers LM; Omene C; Lens SM; Lederman S; van Lier RA; van Oers MH; Eldering E
Leukemia; 2002 Sep; 16(9):1735-44. PubMed ID: 12200688
[TBL] [Abstract][Full Text] [Related]
15. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
[TBL] [Abstract][Full Text] [Related]
16. CD45 ligation induces programmed cell death in T and B lymphocytes.
Klaus SJ; Sidorenko SP; Clark EA
J Immunol; 1996 Apr; 156(8):2743-53. PubMed ID: 8609392
[TBL] [Abstract][Full Text] [Related]
17. CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism.
Dranitzki-Elhalel M; Huang JH; Sasson M; Rachmilewitz J; Parnas M; Tykocinski ML
Int Immunol; 2007 Apr; 19(4):355-63. PubMed ID: 17314083
[TBL] [Abstract][Full Text] [Related]
18. Activation-induced apoptosis and cell surface expression of Fas (CD95) ligand are reciprocally regulated by retinoic acid receptor alpha and gamma and involve nur77 in T cells.
Tóth R; Szegezdi E; Reichert U; Bernardon JM; Michel S; Ancian P; Kis-Tóth K; Macsári Z; Fésüs L; Szondy Z
Eur J Immunol; 2001 May; 31(5):1382-91. PubMed ID: 11465095
[TBL] [Abstract][Full Text] [Related]
19. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
20. T cell activation by cross-linking anti-CD3 antibodies with second anti-T cell antibodies: dual antibody cross-linking mimics physical monocyte interaction.
Walker C; Bettens F; Pichler WJ
Eur J Immunol; 1987 Nov; 17(11):1611-8. PubMed ID: 2960544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
